|
Not far from the center of the controversy over human embryonic stem cell (hESC) research is Geron. The company hopes to parlay its work into viable therapies for various diseases and conditions. One of the company's lead products is a hESC therapy called GRNOPC1 for spinal cord injury which was approved to enter the world's first hESC human clinical trials until the FDA put a hold on the trials while the agency reviewed new data. Geron is also focused on anticancer drug candidate GRN163L, which inhibits telomerase, an enzyme that may prolong cellular life and prevents apoptosis (programmed cell death). Geron has been in business since 1992 and has subsidiaries in Scotland and Hong Kong.
|
| | | Contact Information | |
Address: |
230 Constitution Dr.
Menlo Park, CA 94025
| | Phone: | 650-473-7700 | | Fax: | 650-473-7750 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 2.80 M | | Revenue Growth (1 yr): | (-63.20%) | | Employees (2008): | 159 | | Employee Growth (1 yr): | 13.60% |
|
|
Key People
| | • |
Chairman:
Alexander E. (Alex) Barkas
| | • |
President, CEO, and Director; President, Oncology:
Thomas B. Okarma
| | • |
EVP, CFO, Treasurer, and Secretary:
David L. Greenwood
|
|
|
